Form 4: ImageneBio CFO Jotin Marango Reports Post-Merger Stock Transactions

ImageneBio, Inc.'s Chief Financial Officer, Jotin Marango, reported the acquisition of common stock and the disposition of shares for tax purposes following the merger between Ikena Oncology and Inmagene Biopharmaceuticals.

Summary

• Jotin Marango, Chief Financial Officer of ImageneBio, Inc., reported transactions related to the recent merger of Ikena Oncology, Inc. (the former company name) and Inmagene Biopharmaceuticals.
• On July 28, 2025, Marango acquired 15,776 shares of ImageneBio Common Stock.
• This acquisition was in connection with the closing of the merger, where options held in Ikena Oncology were exchanged for shares in the combined company.
• On the same date, July 28, 2025, Marango disposed of 4,630 shares of Common Stock at a price of $17.16 per share. This disposition was likely for tax withholding purposes related to the share acquisition.
• Following these transactions, Marango directly beneficially owns 11,146 shares of ImageneBio Common Stock.
• Derivative securities, specifically stock options to buy 181,000, 105,000, and 397,199 shares, were disposed of on July 25, 2025, as part of the merger-related exchange, resulting in zero beneficially owned derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a disposition of shares, it's for tax purposes, which is standard. The underlying event is a merger, and the CFO is receiving shares in the new entity, indicating continued involvement and alignment with shareholder interests.

Positives

• Acquisition of 15,776 shares of common stock by the CFO, indicating continued equity interest in the combined entity post-merger.

Negatives

• Disposal of 4,630 shares of common stock at $17.16, likely for tax withholding, which reduces direct ownership.

Future Outlook

NA

Industry Context

This filing reflects a routine insider transaction following a corporate merger in the biotechnology or pharmaceutical industry, where equity compensation structures are adjusted to reflect the new combined entity.

Stakeholder Impact

• Shareholders: The transactions reflect the post-merger equity structure for a key executive, providing transparency on insider holdings. The disposition for tax purposes is a routine event and does not indicate a lack of confidence.
• Employees: The merger and subsequent equity adjustments impact employees who held options in the pre-merger entity.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by the Chief Financial Officer following a corporate merger. The acquisition of shares is a conversion from pre-merger options, and the disposition is for tax withholding. These are standard events and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell.

Keywords

ImageneBio, IMA, Jotin Marango, CFO, SEC Form 4, Insider Trading, Stock Transaction, Merger, Ikena Oncology, Inmagene Biopharmaceuticals, Equity, Options, Common Stock